Advertisement

Immunologic Research

, Volume 66, Issue 6, pp 726–736 | Cite as

Routinely utilized in-house assays for infliximab, adalimumab and their anti-drug antibody levels

  • Manca Ogrič
  • Polona Žigon
  • David Drobne
  • Borut Štabuc
  • Snezna Sodin-Semrl
  • Saša ČučnikEmail author
  • Sonja Praprotnik
Original Article

Abstract

By monitoring serum concentrations of infliximab (IFX) and adalimumab (ADL) and levels of their antibodies in patients with inflammatory diseases, clinicians can adjust dose and increase safety and effectiveness of treatment. The aim was to develop and validate in-house enzyme-linked immunosorbent assays (ELISAs) for IFX and ADL, together with anti-IFX and anti-ADL ELISAs for routine detection and further analysis with acid dissociation of immune complexes. Furthermore, the objectives were to compare in-house assays with commercial ELISAs and reporter gene assays (RGAs) and to determine cross-reactivity between original Remicade®/Remsima™ and their antibodies. In-house ELISAs were validated (imprecision, accuracy among other criteria) and compared with commercial apDia ELISAs and RGAs. Correlation coefficients, intraclass correlation coefficients, agreement, and bias were calculated. All in-house ELISAs gave precise and repeatable results. The immune complexes between IFX and anti-IFX were found in 3% of samples, while complexes between ADL and anti-ADL were found in 14% of samples. Significant correlations were found between in-house and apDia ELISAs and RGA for IFX, ADL, anti-IFX, and anti-ADL results. Remicade®, Remsima™, and their antibodies could be accurately measured with either apDia or in-house IFX and anti-IFX ELISAs. Accurate and precise in-house ELISAs, highly comparable with commercial ELISAs and RGAs, were developed and validated for routine analysis of samples of patients treated with IFX (Remicade® or Remsima™) or ADL providing substantial cost benefit. Complex dissociation identified samples with anti-IFX-IFX (3%) and anti-ADL-ADL (14%) complexes indicating the benefit of adding acid dissociation to therapeutic drug monitoring of IFX and ADL.

Keywords

Infliximab Adalimumab Anti-drug antibodies ELISA Reporter gene assay Biosimilars 

Notes

Acknowledgments

The authors would like to thank all the staff in the Department of Rheumatology and the Immunology Laboratory, who helped collect and process the patient samples.

Research funding

The authors received financial support from the Slovenian Research Agency for funding the National Research Program “Systemic Autoimmune Diseases” (No. P3-0314).

Author contributions

All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Compliance with ethical standards

 This study was conducted as part of the National Research Program (No. P3-0314) and has been approved by the Slovenian Ethical Committee (#99/04/15 and #38/01/16). It has therefore been performed in accordance with the ethical standards laid down in 1964 Declaration of Helsinki and its later amendments. Informed consent was obtained from all individuals included in this study.

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205–19.  https://doi.org/10.1056/NEJMra1004965.CrossRefGoogle Scholar
  2. 2.
    Ambarus C, Yeremenko N, Tak PP, Baeten D. Pathogenesis of spondyloarthritis: autoimmune or autoinflammatory? Curr Opin Rheumatol. 2012;24(4):351–8.  https://doi.org/10.1097/BOR.0b013e3283534df4.CrossRefGoogle Scholar
  3. 3.
    Barnas JL, Ritchlin CT. Etiology and pathogenesis of psoriatic arthritis. Rheum Dis Clin N Am. 2015;41(4):643–63.  https://doi.org/10.1016/j.rdc.2015.07.006.CrossRefGoogle Scholar
  4. 4.
    Geremia A, Biancheri P, Allan P, Corazza GR, Di Sabatino A. Innate and adaptive immunity in inflammatory bowel disease. Autoimmun Rev. 2014;13(1):3–10.  https://doi.org/10.1016/j.autrev.2013.06.004.CrossRefGoogle Scholar
  5. 5.
    Kalliolias GD, Ivashkiv LB. TNF biology, pathogenic mechanisms and emerging therapeutic strategies. Nat Rev Rheumatol. 2016;12(1):49–62.  https://doi.org/10.1038/nrrheum.2015.169.CrossRefGoogle Scholar
  6. 6.
    Anderson DL. A new age in rheumatoid arthritis treatment. Am J Nurs. 2004;104(2):60–8.CrossRefGoogle Scholar
  7. 7.
    Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117(2):244–79.  https://doi.org/10.1016/j.pharmthera.2007.10.001.CrossRefGoogle Scholar
  8. 8.
    Gionchetti P, Dignass A, Danese S, Magro Dias FJ, Rogler G, Lakatos PL, et al. 3. EUROPEAN Evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: Part 2: surgical management and special situations. J Crohn's Colitis. 2017;11(2):135–49.  https://doi.org/10.1093/ecco-jcc/jjw169.
  9. 9.
    Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel JF, Allez M, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis. 2012;6(10):991–1030.  https://doi.org/10.1016/j.crohns.2012.09.002.CrossRefGoogle Scholar
  10. 10.
    Nam JL, Winthrop KL, van Vollenhoven RF, Pavelka K, Valesini G, Hensor EM, et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis. 2010;69(6):976–86.  https://doi.org/10.1136/ard.2009.126573.CrossRefGoogle Scholar
  11. 11.
    Mantzaris GJ. Anti-TNFs: originators and biosimilars. Dig Dis (Basel, Switzerland). 2016;34(1–2):132–9.  https://doi.org/10.1159/000443128.CrossRefGoogle Scholar
  12. 12.
    Pisupati K, Benet A, Tian Y, Okbazghi S, Kang J, Ford M, et al. Biosimilarity under stress: a forced degradation study of Remicade(R) and Remsima. mAbs. 2017;9:1–13.  https://doi.org/10.1080/19420862.2017.1347741.CrossRefGoogle Scholar
  13. 13.
    Yoo DH, Oh C, Hong S, Park W. Analysis of clinical trials of biosimilar infliximab (CT-P13) and comparison against historical clinical studies with the infliximab reference medicinal product. Expert Rev Clin Immunol. 2015;11(Suppl 1):S15–24.  https://doi.org/10.1586/1744666x.2015.1090314.CrossRefGoogle Scholar
  14. 14.
    Melmed GY, Irving PM, Jones J, Kaplan GG, Kozuch PL, Velayos FS, et al. Appropriateness of testing for anti-tumor necrosis factor agent and antibody concentrations, and interpretation of results. Clin Gastroenterol Hepatol. 2016;14(9):1302–9.  https://doi.org/10.1016/j.cgh.2016.05.010.CrossRefGoogle Scholar
  15. 15.
    Baert F, Noman M, Vermeire S, Van Assche G, G DH, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med. 2003;348(7):601–8.  https://doi.org/10.1056/NEJMoa020888.CrossRefGoogle Scholar
  16. 16.
    Bendtzen K. Immunogenicity of anti-TNF-α biotherapies: II. Clinical relevance of methods used for anti-drug antibody detection. Front Immunol. 2015;6.  https://doi.org/10.3389/fimmu.2015.00109.
  17. 17.
    van Schouwenburg PA, Bartelds GM, Hart MH, Aarden L, Wolbink GJ, Wouters D. A novel method for the detection of antibodies to adalimumab in the presence of drug reveals “hidden” immunogenicity in rheumatoid arthritis patients. J Immunol Methods. 2010;362(1–2):82–8.  https://doi.org/10.1016/j.jim.2010.09.005.CrossRefGoogle Scholar
  18. 18.
    Hart MH, de Vrieze H, Wouters D, Wolbink G-J, Killestein J, de Groot ER, et al. Differential effect of drug interference in immunogenicity assays. J Immunol Methods. 2011;372(1–2):196–203.  https://doi.org/10.1016/j.jim.2011.07.019.CrossRefGoogle Scholar
  19. 19.
    Van Stappen T, Brouwers E, Vermeire S, Gils A. Validation of a sample pretreatment protocol to convert a drug-sensitive into a drug-tolerant anti-infliximab antibody immunoassay. Drug Test Anal. 2017;9(2):243–7.  https://doi.org/10.1002/dta.1968.CrossRefGoogle Scholar
  20. 20.
    Ogric M, Tercelj M, Praprotnik S, Tomsic M, Bozic B, Sodin-Semrl S, et al. Detection of adalimumab and anti-adalimumab antibodies in patients with rheumatoid arthritis: a comprehensive overview of methodology pitfalls and benefits. Immunol Res. 2017;65(1):172–85.  https://doi.org/10.1007/s12026-016-8824-8.CrossRefGoogle Scholar
  21. 21.
    Darrouzain F, Bian S, Desvignes C, Bris C, Watier H, Paintaud G, et al. Immunoassays for measuring serum concentrations of monoclonal antibodies and anti-biopharmaceutical antibodies in patients. Ther Drug Monit. 2017;39(4):316–21.  https://doi.org/10.1097/ftd.0000000000000419.CrossRefGoogle Scholar
  22. 22.
    Wang SL, Ohrmund L, Hauenstein S, Salbato J, Reddy R, Monk P, et al. Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum. J Immunol Methods. 2012;382(1–2):177–88.  https://doi.org/10.1016/j.jim.2012.06.002.CrossRefGoogle Scholar
  23. 23.
    Lallemand C, Kavrochorianou N, Steenholdt C, Bendtzen K, Ainsworth MA, Meritet JF, et al. Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNFalpha antagonists. J Immunol Methods. 2011;373(1–2):229–39.  https://doi.org/10.1016/j.jim.2011.08.022.CrossRefGoogle Scholar
  24. 24.
    Bian S, Ferrante M, Gils A. Validation of a drug-resistant anti-adalimumab antibody assay to monitor immunogenicity in the presence of high concentrations of adalimumab. AAPS J. 2017;19(2):468–74.  https://doi.org/10.1208/s12248-016-0018-8.CrossRefGoogle Scholar
  25. 25.
    Van Stappen T, Brouwers E, Tops S, Geukens N, Vermeire S, Declerck PJ, et al. Generation of a highly specific monoclonal anti-infliximab antibody for harmonization of TNF-coated infliximab assays. Ther Drug Monit. 2015;37(4):479–85.  https://doi.org/10.1097/ftd.0000000000000162.CrossRefGoogle Scholar
  26. 26.
    Bian S, Stappen TV, Baert F, Compernolle G, Brouwers E, Tops S, et al. Generation and characterization of a unique panel of anti-adalimumab specific antibodies and their application in therapeutic drug monitoring assays. J Pharm Biomed Anal. 2016;125:62–7.  https://doi.org/10.1016/j.jpba.2016.03.029.CrossRefGoogle Scholar
  27. 27.
    CLSI (2014) Evaluation of Precision of Quantitative Measurement Procedures; Approved Guideline - Third Edition. CLSI document EP05-A3. Clinical and Laboratory Standards Insitute,Google Scholar
  28. 28.
    Van Stappen T, Billiet T, Vande Casteele N, Compernolle G, Brouwers E, Vermeire S, et al. An optimized anti-infliximab bridging enzyme-linked immunosorbent assay for harmonization of anti-infliximab antibody titers in patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2015;21(9):2172–7.  https://doi.org/10.1097/mib.0000000000000434.CrossRefGoogle Scholar
  29. 29.
    Gils A, Vande Casteele N, Poppe R, Van de Wouwer M, Compernolle G, Peeters M, et al. Development of a universal anti-adalimumab antibody standard for interlaboratory harmonization. Ther Drug Monit. 2014;36(5):669–73.  https://doi.org/10.1097/ftd.0000000000000074.CrossRefGoogle Scholar
  30. 30.
    Vande Casteele N, Ferrante M, Van Assche G, Ballet V, Compernolle G, Van Steen K, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology. 2015;148(7):1320–1329.e1323.  https://doi.org/10.1053/j.gastro.2015.02.031.CrossRefGoogle Scholar
  31. 31.
    Mitrev N, Vande Casteele N, Seow CH, Andrews JM, Connor SJ, Moore GT, et al. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017;46(11–12):1037–53.  https://doi.org/10.1111/apt.14368.CrossRefGoogle Scholar
  32. 32.
    Danese S, Gomollon F. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). J Crohns Colitis. 2013;7(7):586–9.  https://doi.org/10.1016/j.crohns.2013.03.011.CrossRefGoogle Scholar
  33. 33.
    Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol. 2011;106(4):685–98.  https://doi.org/10.1038/ajg.2011.103.CrossRefGoogle Scholar
  34. 34.
    Moots RJ, Xavier RM, Mok CC, Rahman MU, Tsai WC, Al-Maini MH, et al. The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: results from a multinational, real-world clinical practice, non-interventional study. PLoS One. 2017;12(4):e0175207.  https://doi.org/10.1371/journal.pone.0175207.CrossRefGoogle Scholar
  35. 35.
    Vande Casteele N, Feagan BG, Gils A, Vermeire S, Khanna R, Sandborn WJ, et al. Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives. Curr Gastroenterol Rep. 2014;16(4):378.  https://doi.org/10.1007/s11894-014-0378-0.CrossRefGoogle Scholar
  36. 36.
    Gils A, Van Stappen T, Dreesen E, Storme R, Vermeire S, Declerck PJ. Harmonization of infliximab and anti-infliximab assays facilitates the comparison between originators and biosimilars in clinical samples. Inflamm Bowel Dis. 2016;22(4):969–75.  https://doi.org/10.1097/mib.0000000000000709.CrossRefGoogle Scholar
  37. 37.
    Schmitz EM, van de Kerkhof D, Hamann D, van Dongen JL, Kuijper PH, Brunsveld L, et al. Therapeutic drug monitoring of infliximab: performance evaluation of three commercial ELISA kits. Clin Chem Lab Med. 2016;54(7):1211–9.  https://doi.org/10.1515/cclm-2015-0987.CrossRefGoogle Scholar
  38. 38.
    Bloem K, van Leeuwen A, Verbeek G, Nurmohamed MT, Wolbink GJ, van der Kleij D, et al. Systematic comparison of drug-tolerant assays for anti-drug antibodies in a cohort of adalimumab-treated rheumatoid arthritis patients. J Immunol Methods. 2015;418:29–38.  https://doi.org/10.1016/j.jim.2015.01.007.CrossRefGoogle Scholar
  39. 39.
    Vande Casteele N, Buurman DJ, Sturkenboom MG, Kleibeuker JH, Vermeire S, Rispens T, et al. Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays. Aliment Pharmacol Ther. 2012;36(8):765–71.  https://doi.org/10.1111/apt.12030.CrossRefGoogle Scholar
  40. 40.
    van Bezooijen JS, Koch BC, van Doorn MB, Prens EP, van Gelder T, Schreurs MW. Comparison of three assays to quantify infliximab, adalimumab, and etanercept serum concentrations. Ther Drug Monit. 2016;38(4):432–8.  https://doi.org/10.1097/ftd.0000000000000310.CrossRefGoogle Scholar
  41. 41.
    Steenholdt C, Ainsworth MA, Tovey M, Klausen TW, Thomsen OO, Brynskov J, et al. Comparison of techniques for monitoring infliximab and antibodies against infliximab in Crohn’s disease. Ther Drug Monit. 2013;35(4):530–8.  https://doi.org/10.1097/FTD.0b013e31828d23c3.CrossRefGoogle Scholar
  42. 42.
    Lazar-Molnar E, Delgado JC. Immunogenicity assessment of tumor necrosis factor antagonists in the clinical laboratory. Clin Chem. 2016;62(9):1186–98.  https://doi.org/10.1373/clinchem.2015.242875.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Manca Ogrič
    • 1
    • 2
  • Polona Žigon
    • 1
  • David Drobne
    • 3
    • 4
  • Borut Štabuc
    • 3
    • 4
  • Snezna Sodin-Semrl
    • 1
    • 5
  • Saša Čučnik
    • 1
    • 2
    Email author
  • Sonja Praprotnik
    • 1
  1. 1.Department of RheumatologyUniversity Medical Centre LjubljanaLjubljanaSlovenia
  2. 2.Faculty of Pharmacy, Chair of Clinical BiochemistryUniversity of LjubljanaLjubljanaSlovenia
  3. 3.Department of GastroenterologyUniversity Medical Centre LjubljanaLjubljanaSlovenia
  4. 4.Faculty of MedicineUniversity of LjubljanaLjubljanaSlovenia
  5. 5.Faculty of Mathematics, Natural Sciences and Information TechnologiesUniversity of PrimorskaKoperSlovenia

Personalised recommendations